Syngene’s new CEO to commence office in Mar ‘16

Indian CRO Syngene International today announced the appointment of Mr Jonathan Hunt as CEO-designate


Mr Jonathan Hunt

Mr Hunt will take charge as CEO post the retirement of current CEO Mr Peter Bains in March 2016.

Mr Bains, who has worked closely with Syngene as a Director since 2010 and was appointed as the CEO in February, 2015 will continue as a member of the Syngene Board post his retirement.

Commenting on the new appointment, Dr Kiran Mazumdar Shaw, Managing Director, Syngene International said, "We are extremely delighted to have Jonathan Hunt join the Syngene executive leadership team. After the resounding success of its IPO earlier during the year, Syngene is now at an exciting phase of its journey of transforming from a CRO to a full-fledged CRAMs player. Jonathan has a rich experience in the global biopharmaceutical industry and a proven track record of leading transformational change and delivering growth. We are sure, under his leadership, Syngene will continue to strengthen its position in the global CRAMs market."

In his new role, Mr Hunt will be responsible for strengthening Syngene's relations with its existing global customers as well as forging new relationships.

He will also steer the company's investments in developing and strengthening its capabilities and capacities to augment Syngene's service offerings.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email